Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7738139 | 0.88 | NPC1 (0.41) | SMN1; SMN2IKBKBNPC1RAB9AALDH1A1 | |
| SCHEMBL16399868 | 0.86 | NOTUM (0.49) | SMN1; SMN2IKBKBNPC1RAB9AALDH1A1 | |
| SCHEMBL18003599 | 0.86 | GCGR (0.46) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL1050172 | 0.84 | NPC1 (0.41) | SMN1; SMN2IKBKBNPC1RAB9AALDH1A1 | |
| SCHEMBL18003565 | 0.82 | IKBKB (0.43) | SMN1; SMN2IKBKBNPC1RAB9AALDH1A1 | |
| SCHEMBL18003443 | 0.81 | KDM4E (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL4925692 | 0.80 | TP53 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL18003337 | 0.80 | GCGR (0.42) | ALDH1A1POLBKMT2AGAA | |
| SCHEMBL18002992 | 0.80 | NOTUM (0.42) | SMN1; SMN2NPC1RAB9AALDH1A1HSD17B10 | |
| SCHEMBL18003440 | 0.79 | PPARG (0.42) | HPGDKDM4ENPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872034-B2 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-18 | — | — | US | disclosed |
| US-7872034-B2 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-18 | — | — | US | disclosed |
| US-7872034-B2 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-18 | — | — | US | disclosed |
| EP-1599455-B1 | 4-(3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXYLOXY)-BUTANE ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR TREATING DIABETES OF TYPE 2 AND ATHEROSCLEROSIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-01 | — | — | EP | disclosed |
| EP-1599455-B1 | 4-(3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXYLOXY)-BUTANE ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR TREATING DIABETES OF TYPE 2 AND ATHEROSCLEROSIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-01 | — | — | EP | disclosed |
| EP-1599453-B1 | 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-05-06 | — | — | EP | disclosed |
| EP-1599453-B1 | 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080167354-A1 | ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167354-A1 | ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167354-A1 | ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-1599452-B1 | 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-06-20 | — | — | EP | disclosed |
| EP-1599453-A1 | 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-1599455-A1 | 4-(3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXYLOXY)-BUTANE ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR TREATING DIABETES OF TYPE 2 AND ATHEROSCLEROSIS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-1599452-A1 | 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20050215596-A1 | Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-29 | — | — | US | disclosed |
| US-20050101637-A1 | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-05-12 | — | — | US | disclosed |
| US-20040209920-A1 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004076426-A1 | 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANECARBONYL-AMINO BUTYRIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076428-A1 | 4-(3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXYLOXY)-BUTANE ACID DERIVATIVES AND RELATED COMPOUNDS AS PPAR MODULATORS FOR TREATING DIABETES OF TYPE 2 AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076427-A1 | 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167354-A1 | ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, FFAR1, FFAR2 | SMN1; SMN2 2586/4885IKBKB 572/4885NPC1 506/4885 |
| US-20050215596-A1 | Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals | DNPEP, DDC, AADAT | SMN1; SMN2 3984/4885IKBKB 1928/4885NPC1 657/4885 |
| US-20040209920-A1 | Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals | GPR119, FFAR1, FFAR2 | SMN1; SMN2 2706/4885IKBKB 652/4885NPC1 377/4885 |
| US-20050101637-A1 | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | GPR119, PC, CPT1A | SMN1; SMN2 1912/4885IKBKB 1045/4885NPC1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.